🇺🇸 FDA

Intelligence · Patent portfolio

Vanda Pharmaceuticals Netherlands Patents

Full USPTO pharma patent portfolio for Vanda Pharmaceuticals Netherlands — grant dates, expiration, and drug cross-links.

Patents
96
Expiring ≤24m
0

Quick answer

Vanda Pharmaceuticals Netherlands has 96 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Page 2 of 2

  1. US 10610510

    Treatment of circadian rhythm disorders

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10611744

    Highly purified pharmaceutical grade tasimelteon

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10610511

    Method of treatment

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10570453

    Method of predicting a predisposition to QT prolongation

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10570452

    Method of predicting a predisposition to QT prolongation

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10563259

    Method of treatment based on polymorphisms of the KCNQ1 gene

    Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10563261

    Method of predicting a predisposition to QT prolongation

    Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10563260

    Method of predicting a predisposition to QT prolongation

    Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10463655

    Method of treatment with tradipitant

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10449176

    Treatment of circadian rhythm disorders

    Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10441580

    Iloperidone for the treatment of schizophrenia

    Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10376487

    Method of treatment

    Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10272075

    Method and composition for treating an alpha adrenoceptor-mediated condition

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10272076

    Methods for the administration of iloperidone

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10265282

    Cancer treatment

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10233142

    Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10179119

    Method of treatment

    Expires Mon Jan 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10149829

    Treatment of circadian rhythm disorders

    Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10071977

    Highly purifid pharmaceutical grade tasimelteon

    Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9987264

    Method and composition for treating a serotonin receptor-mediated condition

    Expires Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9855241

    Treatment of circadian rhythm disorders

    Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9850199

    Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide

    Expires Mon Dec 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9730910

    Treatment of circadian rhythm disorders

    Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9708291

    Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl)-(2-chlorophenyl)-methanone

    Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9617203

    Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide

    Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9549913

    Treatment of circadian rhythm disorders

    Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9539234

    Treatment of circadian rhythm disorders

    Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9458507

    Antipsychotic treatment based on SNP genotype

    Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9446038

    Method and composition for treating a serotonin receptor-mediated condition

    Expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9408839

    Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype

    Expires Mon Aug 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9328387

    Antipsychotic treatment based on SNP genotype

    Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9243295

    Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype

    Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9212129

    Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide

    Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9157121

    Method of treatment based on polymorphisms of the KCNQ1 gene

    Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9138432

    Methods for the administration of iloperidone

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9072742

    Method of predicting a predisposition to QT prolongation

    Expires Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9074255

    Method of predicting a predisposition to QT prolongation

    Expires Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9074254

    Method of predicting a predisposition to QT prolongation

    Expires Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9074256

    Method of predicting a predisposition to QT prolongation

    Expires Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9060995

    Treatment of circadian rhythm disorders

    Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9057104

    Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype

    Expires Mon Jun 11 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8999638

    Method of treatment based on polymorphisms of the KCNQ1 gene

    Expires Mon Apr 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8865210

    Stable dosage formulations of imidazolylalkyl-pyridines

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8785492

    Treatment of circadian rhythm disorders

    Expires Mon Jul 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8729100

    Method and composition for treating an alpha adrenoceptor-mediated condition

    Expires Mon May 15 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8652776

    Prediction of QT prolongation based on SNP genotype

    Expires Mon Feb 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8618134

    Method and composition for treating a serotonin receptor-mediated condition

    Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8586610

    Methods for the administration of iloperidone

    Expires Mon Nov 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Vanda Pharmaceuticals Netherlands have?

96 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Vanda Pharmaceuticals Netherlands patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.